AQR Capital Management’s Bicara Therapeutics BCAX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCAX
SL
AQR Capital Management's BCAX Position: Q3 2026 in Review
AQR Capital Management increased its Bicara Therapeutics (BCAX) stake by 6.2% in Q3 2026, buying an estimated $46.1K and bringing the position to 31,758 shares worth $591K. The position accounts for ﹤0.01% of the portfolio, ranked #3344.
AQR Capital Management first reported a position in BCAX in Q1 2025 and has held it in 4 quarters since. The position peaked at $888K in Q2 2026. 169 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.
- AQR Capital Management held 31,758 shares of Bicara Therapeutics worth $591K as of Q3 2026.
- AQR Capital Management bought 1,841 Bicara Therapeutics shares in Q3 2026, an estimated $46.1K.
- Bicara Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q3 2026, its #3344 holding.
- AQR Capital Management first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 4 quarters since.
- AQR Capital Management's Bicara Therapeutics position peaked at $888K in Q2 2026.
- 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.
Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.